Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -954.9 Million INR | 67.54% |
| 2022 | -2.94 Billion INR | -62.25% |
| 2021 | -1.81 Billion INR | -24.07% |
| 2020 | -1.46 Billion INR | -14.73% |
| 2019 | -1.27 Billion INR | -115.19% |
| 2018 | -592 Million INR | 33.36% |
| 2017 | -888.4 Million INR | -96.85% |
| 2016 | -451.3 Million INR | -218.86% |
| 2015 | 379.7 Million INR | 158.97% |
| 2014 | -643.9 Million INR | -191.87% |
| 2013 | 700.9 Million INR | -10.84% |
| 2012 | 786.1 Million INR | 21.66% |
| 2011 | 646.15 Million INR | -63.26% |
| 2010 | 1.75 Billion INR | -17.48% |
| 2009 | 2.13 Billion INR | -11.99% |
| 2008 | 2.42 Billion INR | 44.33% |
| 2007 | 1.67 Billion INR | 54.04% |
| 2006 | 1.08 Billion INR | 18.85% |
| 2005 | 916.43 Million INR | -2.64% |
| 2004 | 941.28 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 4.59 Billion INR | 581.24% |
| 2024 Q2 | -614.7 Million INR | -106.77% |
| 2023 Q3 | 4.75 Billion INR | 307.86% |
| 2023 Q1 | 8.4 Billion INR | 385.55% |
| 2023 FY | -954.9 Million INR | 67.54% |
| 2023 Q4 | -954.9 Million INR | -120.08% |
| 2023 Q2 | -2.28 Billion INR | -127.23% |
| 2022 Q3 | 6.14 Billion INR | 304.66% |
| 2022 Q2 | -3 Billion INR | -191.5% |
| 2022 Q1 | 3.28 Billion INR | 281.01% |
| 2022 FY | -2.94 Billion INR | -62.25% |
| 2022 Q4 | -2.94 Billion INR | -147.86% |
| 2021 Q4 | -1.81 Billion INR | -131.86% |
| 2021 FY | -1.81 Billion INR | -24.07% |
| 2021 Q1 | 3.78 Billion INR | 358.76% |
| 2021 Q2 | -2.08 Billion INR | -155.16% |
| 2021 Q3 | 5.69 Billion INR | 372.84% |
| 2020 Q3 | 4.81 Billion INR | 398.88% |
| 2020 Q4 | -1.46 Billion INR | -130.35% |
| 2020 FY | -1.46 Billion INR | -14.73% |
| 2020 Q2 | -1.61 Billion INR | -159.79% |
| 2020 Q1 | 2.69 Billion INR | 311.55% |
| 2019 FY | -1.27 Billion INR | -115.19% |
| 2019 Q4 | -1.27 Billion INR | -139.65% |
| 2019 Q3 | 3.21 Billion INR | 1963.46% |
| 2019 Q2 | -172.4 Million INR | -110.78% |
| 2019 Q1 | 1.59 Billion INR | 370.1% |
| 2018 Q3 | 2.6 Billion INR | 483.83% |
| 2018 Q2 | -679 Million INR | -124.87% |
| 2018 Q1 | 2.73 Billion INR | 407.32% |
| 2018 FY | -592 Million INR | 33.36% |
| 2018 Q4 | -592 Million INR | -122.72% |
| 2017 FY | -888.4 Million INR | -96.85% |
| 2017 Q3 | 3.1 Billion INR | 585.13% |
| 2017 Q2 | -640.4 Million INR | -127.43% |
| 2017 Q1 | 2.33 Billion INR | 617.39% |
| 2017 Q4 | -888.4 Million INR | -128.6% |
| 2016 Q4 | -451.3 Million INR | -116.77% |
| 2016 FY | -451.3 Million INR | -218.86% |
| 2016 Q3 | 2.69 Billion INR | 520.93% |
| 2016 Q2 | -639.2 Million INR | -152.67% |
| 2016 Q1 | 1.21 Billion INR | 219.59% |
| 2015 Q1 | 1.56 Billion INR | 342.62% |
| 2015 FY | 379.7 Million INR | 158.97% |
| 2015 Q4 | 379.7 Million INR | -82.42% |
| 2015 Q3 | 2.16 Billion INR | 449.75% |
| 2015 Q2 | -617.7 Million INR | -139.54% |
| 2014 FY | -643.9 Million INR | -191.87% |
| 2014 Q4 | -643.9 Million INR | 0.0% |
| 2014 Q1 | 1.15 Billion INR | 0.0% |
| 2013 FY | 700.9 Million INR | -10.84% |
| 2012 FY | 786.1 Million INR | 21.66% |
| 2011 FY | 646.15 Million INR | -63.26% |
| 2010 FY | 1.75 Billion INR | -17.48% |
| 2009 FY | 2.13 Billion INR | -11.99% |
| 2008 FY | 2.42 Billion INR | 44.33% |
| 2007 FY | 1.67 Billion INR | 54.04% |
| 2006 FY | 1.08 Billion INR | 18.85% |
| 2005 FY | 916.43 Million INR | -2.64% |
| 2004 FY | 941.28 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 124.701% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 125.855% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 66.408% |
| Granules India Limited | 9.28 Billion INR | 110.282% |
| Indoco Remedies Limited | 6.47 Billion INR | 114.745% |
| Achyut Healthcare Limited | -3.74 Million INR | -25391.191% |
| Alkem Laboratories Limited | -1.6 Billion INR | 40.667% |
| Alpa Laboratories Limited | 35.36 Million INR | 2800.28% |
| Brooks Laboratories Limited | 49.48 Million INR | 2029.676% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 80.949% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 128.946% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 17.521% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 107.395% |
| Eris Lifesciences Limited | 13.8 Billion INR | 106.916% |
| FDC Limited | -57.75 Million INR | -1553.449% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 77.717% |
| Gufic Biosciences Limited | 3.19 Billion INR | 129.894% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 77.007% |
| Ipca Laboratories Limited | 11.41 Billion INR | 108.365% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 31.299% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 149.402% |
| Lasa Supergenerics Limited | 205.79 Million INR | 563.996% |
| Laurus Labs Limited | 24.38 Billion INR | 103.916% |
| Lupin Limited | 17.19 Billion INR | 105.554% |
| Mankind Pharma Limited | -9.9 Billion INR | 90.362% |
| Medicamen Biotech Limited | 160.31 Million INR | 695.636% |
| Medico Remedies Limited | 78.67 Million INR | 1313.697% |
| Megasoft Limited | 1.28 Billion INR | 174.279% |
| NATCO Pharma Limited | -5.81 Billion INR | 83.584% |
| Piramal Pharma Limited | 42.27 Billion INR | 102.259% |
| RPG Life Sciences Limited | -364.7 Million INR | -161.832% |
| Sigachi Industries Limited | 859.94 Million INR | 211.041% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 98.682% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 758.661% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 2166.391% |
| Unichem Laboratories Limited | 931.91 Million INR | 202.466% |
| Wanbury Limited | 1.1 Billion INR | 186.348% |
| Windlas Biotech Limited | -273.04 Million INR | -249.729% |
| ZIM Laboratories Limited | 983.6 Million INR | 197.082% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 124.41% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -1.391% |
| Divi's Laboratories Limited | -39.77 Billion INR | 97.599% |
| Hester Biosciences Limited | 2.29 Billion INR | 141.685% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 59.331% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -283.815% |
| Bal Pharma Limited | 1.26 Billion INR | 175.572% |
| Strides Pharma Science Limited | 23.25 Billion INR | 104.106% |
| Venus Remedies Limited | -267.7 Million INR | -256.705% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 136.56% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 115.508% |
| Shilpa Medicare Limited | 9.06 Billion INR | 110.529% |
| Aarti Drugs Limited | 5.54 Billion INR | 117.21% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 13.293% |
| Suven Life Sciences Limited | -1.63 Billion INR | 41.514% |
| Ind-Swift Limited | 9.5 Billion INR | 110.042% |
| Valiant Laboratories Limited | -295.03 Million INR | -223.66% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 133.847% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 109.521% |
| Themis Medicare Limited | 764.96 Million INR | 224.83% |
| Hikal Limited | 7.96 Billion INR | 111.986% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 103.0% |
| Sequent Scientific Limited | 4.17 Billion INR | 122.852% |
| Novartis India Limited | -5.89 Billion INR | 83.791% |
| Wockhardt Limited | 18.27 Billion INR | 105.227% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 103.527% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -5076.732% |
| Neuland Laboratories Limited | -214.05 Million INR | -346.094% |
| Morepen Laboratories Limited | -231.17 Million INR | -313.065% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 895.491% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 197.857% |